About: Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates
Creator	Alcaro, Stefano Coricello, Adriana Lupia, Antonio Maruca, Annalisa Mesiti, Francesco
Source	Medline; PMC
abstract	The mechanisms of inflammation and cancer are intertwined by complex networks of signaling pathways. Dysregulations in the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway underlie several pathogenic conditions related to chronic inflammatory states, autoimmune diseases and cancer. Historically, the potential application of JAK inhibition has been thoroughly explored, thus triggering an escalation of favorable results in this field. So far, five JAK inhibitors have been approved by the Food and Drug Administration (FDA) for the treatment of different diseases. Considering the complexity of JAK-depending processes and their involvement in multiple disorders, JAK inhibitors are the perfect candidates for drug repurposing and for the assessment of multitarget strategies. Herein we reviewed the recent progress concerning JAK inhibition, including the innovations provided by the release of JAKs crystal structures and the improvement of synthetic strategies aimed to simplify of the industrial scale-up.
has issue date	2020-07-22(xsd:dateTime)
bibo:doi	10.3390/molecules25153321
bibo:pmid	32707925
has license	cc-by
sha1sum (hex)	c74ce5464f754301499d7537e87810f46e69c454
schema:url	https://doi.org/10.3390/molecules25153321
resource representing a document's title	Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates
has PubMed Central identifier	PMC7435994
has PubMed identifier	32707925
schema:publication	Molecules
resource representing a document's body	covid:c74ce5464f754301499d7537e87810f46e69c454#body_text
is schema:about of	named entity 'RESULTS' named entity 'INFLAMMATION' named entity 'SIGNALING PATHWAYS' named entity 'PROGRESS' named entity 'DISORDERS' named entity 'RELATED' named entity 'SIMPLIFY' named entity 'CANCER' named entity 'COMPLEX' named entity 'FIELD' named entity 'INFLAMMATORY' named entity 'CONDITIONS' named entity 'ESCALATION' named entity 'STRATEGIES' named entity 'HAVE' named entity 'DISEASES' named entity 'FDA' named entity 'inflammation' named entity 'Food and Drug Administration' named entity 'polypharmacology' named entity 'receptor' named entity 'ankylosing spondylitis' named entity 'JAKs' named entity 'baricitinib' named entity 'natural compound' named entity 'protecting group' named entity 'lymphoid tissues' named entity 'baricitinib' named entity 'synthons' named entity 'natural killer cells' named entity 'peroxybenzoic acid' named entity 'pyrazole' named entity 'clinical trials' named entity 'TYK2' named entity 'methyl' named entity 'nucleophilic substitution' named entity 'pharmacological' named entity 'phototoxic' named entity 'inflammatory diseases' named entity 'pyrazole' named entity 'FDA' named entity 'BTK' named entity 'tuberculosis' named entity 'amino group' named entity 'piperidine' named entity 'glucocorticoid' named entity 'JAKs' named entity 'TYK2' named entity 'alkaline' named entity 'cyclopentyl' named entity 'rheumatoid arthritis' named entity 'protein tyrosine kinases' named entity 'pyrazole' named entity 'Ruxolitinib' named entity 'fedratinib' named entity 'autoimmune diseases' named entity 'tofacitinib' named entity 'alcohol' named entity 'cytokine' named entity 'high-affinity' named entity 'piperidine' named entity 'therapeutic agents' named entity 'off-label' named entity 'hydrolyzed' named entity 'amine' named entity 'JAK2' named entity 'cytokine' named entity 'ruxolitinib' named entity 'physiological functions' named entity 'cell growth' named entity 'hydrogen bond' named entity 'Michael reaction' named entity 'anti-inflammatory' named entity 'JAKs' named entity 'tofacitinib' named entity 'LiBF4' named entity 'hormones'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software